Performance of the Large Language Models in African rheumatology: a diagnostic test accuracy study of ChatGPT-4, Gemini, Copilot, and Claude artificial intelligence
Yannick Laurent Tchenadoyo Bayala, Wendlassida Joëlle Stéphanie Zabsonré Tiendrébeogo, Dieu‐Donné Ouedraogo, Fulgence Kaboré, Charles Sougué, Rélwendé Aristide Yaméogo, Wendlassida Martin Nacanabo, Ismaël Ayouba Tinni, Aboubakar Ouédraogo, Enselme Zongo
Abstract
BACKGROUND: Artificial intelligence (AI) tools, particularly Large Language Models (LLMs), are revolutionizing medical practice, including rheumatology. However, their diagnostic capabilities remain underexplored in the African context. To assess the diagnostic accuracy of ChatGPT-4, Gemini, Copilot, and Claude AI in rheumatology within an African population. METHODS: This was a cross-sectional analytical study with retrospective data collection, conducted at the Rheumatology Department of Bogodogo University Hospital Center (Burkina Faso) from January 1 to June 30, 2024. Standardized clinical and paraclinical data from 103 patients were submitted to the four AI models. The diagnoses proposed by the AIs were compared to expert-confirmed diagnoses established by a panel of senior rheumatologists. Diagnostic accuracy, sensitivity, specificity, and predictive values were calculated for each AI model. RESULTS: Among the patients enrolled in the study period, infectious diseases constituted the most common diagnostic category, representing 47.57% (n = 49). ChatGPT-4 achieved the highest diagnostic accuracy (86.41%), followed by Claude AI (85.44%), Copilot (75.73%), and Gemini (71.84%). The inter-model agreement was moderate, with Cohen's kappa coefficients ranging from 0.43 to 0.59. ChatGPT-4 and Claude AI demonstrated high sensitivity (> 90%) for most conditions but had lower performance for neoplastic diseases (sensitivity < 67%). Patients under 50 years old had a significantly higher probability of receiving a correct diagnosis with Copilot (OR = 3.36; 95% CI [1.16-9.71]; p = 0.025). CONCLUSION: LLMs, particularly ChatGPT-4 and Claude AI, show high diagnostic capabilities in rheumatology, despite some limitations in specific disease categories. CLINICAL TRIAL NUMBER: Not applicable.